Frank Glavin

Frank Glavin

Company: Orphan Technologies

Job title: CEO


A Novel Enzyme Therapy For Patients With Homocystinuria 11:10 am

• An overview of homocystinuria pathology, epidemiology, unmet need, and cost burden • OT-58’s impact on biochemical and clinical parameters in multiple mouse models of homocystinuria Interim data from Orphan • Technologies ongoing natural history study and an overview of the ongoing U.S. Randomized Placebo Controlled Phase 1/2 clinical studyRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.